AbbVie reports 10% revenue growth, 25% EPS gains, 360 bps margin expansion, and a 14.81x forward P/E with $14.57 EPS guidance. See why ABBV stock is a buy.
AbbVie: The Market Is Getting It Wrong
view original post
AbbVie reports 10% revenue growth, 25% EPS gains, 360 bps margin expansion, and a 14.81x forward P/E with $14.57 EPS guidance. See why ABBV stock is a buy.